Next Generation Sequencing (NGS) Data Analysis

Next Generation Sequencing (NGS) Data Analysis

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach $2.1 Billion by 2030
The global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$738.5 Million in the year 2022, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 13.9% over the period 2022-2030. NGS Data Analysis Services segment is expected to record 14.8% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the NGS Commercial Software segment is estimated at 12.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $279.7 Million, While China is Forecast to Grow at 15.2% CAGR
The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$279.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$229.2 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 13.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 111 Featured) -
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL (Advanced Biological Laboratories) SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Next Generation Sequencing (NGS) Data Analysis - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
NGS Data Analysis: Unraveling Critical Clues to Solve Scientific Problems
NGS Data Analysis: Insights into File Formats & Downstream Analysis
File Formats for NGS Raw Data
NGS Data: Downstream Analysis
Global Market Overview and Prospects
Next-Generation Sequencing (NGS) Data Analysis Market Witnesses Burgeoning Growth
Key Market Drivers and Inhibitors
Market Analysis
US and Europe Lead, Asia-Pacific to Witness Growth
Analysis by Product
Analysis by Workflow
Analysis by Mode
Analysis by Read Length
Analysis by End-Use
Competitive Landscape
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Next Generation Sequencing Market Drives the Demand for NGS Data Analysis
Increasing R&D Activities in NGS
Rising Use of NGS in Drug Discovery Drives Growth of NGS Data Analysis
Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
Technological Advancements in Sequencing Techniques and Data Integration
Research Initiatives for the Development of NGS-based In-vitro Diagnostics
The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
NGS Data Analysis Using Big Data Gains Ground
Improving Regulatory & Reimbursement Scenario for NGS-based Diagnostic Tests
Increase in Genome Mapping Programs
Declining Costs of Genome Sequencing Drive Market Growth
Growth of Long-Read Sequencing to Propel the Market for NGS Data Analysis
Aging Demographics Present Opportunities
Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Growing Prevalence of Chronic Diseases to Boost the Market Prospects
Rising Diabetes Prevalence: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Breakdown of Total Number of Cancer Cases by Region: 2020
Breakdown of Total Number of Cancer Cases by Type: 2020
Market Challenges
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 3: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 4: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Ngs Commercial Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World 7-Year Perspective for Ngs Commercial Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World 7-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 9: World Recent Past, Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 10: World 7-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World 7-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World 7-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 15: World Recent Past, Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 16: World 7-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 20: World 7-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 21: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 22: World 7-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World 7-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 26: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 27: World Next Generation Sequencing (NGS) Data Analysis Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030
III. MARKET ANALYSIS
UNITED STATES
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 29: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 30: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 31: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 35: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
CANADA
TABLE 36: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 37: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 41: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 43: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
JAPAN
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 47: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 49: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
CHINA
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 53: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 55: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 56: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 58: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 59: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
EUROPE
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 61: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 64: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 65: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 66: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 67: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
FRANCE
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 70: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 71: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 72: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 73: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 74: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 76: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 77: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
GERMANY
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 78: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 79: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 80: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 82: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 83: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 84: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 85: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
ITALY
TABLE 86: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 88: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 89: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 90: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 91: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 92: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
UNITED KINGDOM
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 94: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 95: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 96: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 97: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 98: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 100: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 101: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
REST OF EUROPE
TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 103: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 107: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 109: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
ASIA-PACIFIC
Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 113: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 115: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
REST OF WORLD
TABLE 118: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 119: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2024 & 2030
TABLE 120: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 121: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2024 & 2030
TABLE 122: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2024 & 2030
TABLE 124: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 125: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings